AZ using Chinese alliance to beat the bush for new drug leads
This article was originally published in Scrip
Executive Summary
In another sign that mainstream pharma companies are beginning to embrace the potential of traditional medicines, AstraZeneca has entered into an alliance with a leading Chinese university to derive novel cardiovascular drug leads from a herbal compound.